News Briefing channel feed

As­traZeneca's En­her­tu gets BTD for breast can­cer; Centes­sa nabs $300M loan

4 years ago

At­las cre­ates sec­ond op­por­tu­ni­ty fund with $300M; BioN­Tech's col­orec­tal can­cer vac­cine starts PhII tri­al

4 years ago

Spero strikes $125M roy­al­ty deal for cU­TI drug; French firm launch­es $100M ear­ly biotech fund

4 years ago

Te­va set­tles with Louisiana for $18M over opi­oid claims; Video game treat­ment churns out PhII re­sults

4 years ago

French biotech and Pfiz­er find pos­i­tives in da­ta for Ly­me dis­ease vac­cine can­di­date; Al­tim­mune's obe­si­ty drug shows promise in PhI tri­al

4 years ago

Evelo touts PhII win for in­flam­ma­tion pro­gram; In­novent, An­Heart claim in­ter­im PhII suc­cess in NSCLC

4 years ago

Capri­cor's DMD clin­i­cal tri­al meets pri­ma­ry end­points; Delaware court rules against Take­da in Lupron feud

4 years ago

Ox­ford Bio­med­ica sees new in­vest­ment for man­u­fac­tur­ing; Twist gets a part­ner to help build out dis­cov­ery li­braries 

4 years ago

Blue­bird sends blood dis­or­der drug to FDA for ap­proval; CG On­col­o­gy en­ters col­lab­o­ra­tion with Roche for Tecen­triq

4 years ago

Take­da snaps up the Japan­ese rights to an old Shire cast-off; Boehringer In­gel­heim ac­quires Abexxa Bi­o­log­ics

4 years ago

Den­mark's Gubra to col­lab­o­rate with Bay­er on pep­tides; Sam­sung and Bio­gen re­ceive FDA ap­proval for Lu­cen­tis biosim­i­lar

4 years ago

Philip Mor­ris gets share­hold­er back­ing in Vec­tura saga; Tarve­da strikes ex­clu­sive li­cens­ing agree­ment with Sci­Clone

4 years ago

FDA ac­cepts In­tel­li­a's IND for CRISPR and TCR-T cell ther­a­py; San­té clos­es Fund IV at $260M

4 years ago

Three De­mo­c­rat reps op­pose Medicare drug pric­ing plan; Alpine Im­mune an­nounces pri­vate place­ment

4 years ago

Ab­Cellera ac­quires trans­mem­brane pro­tein pro­duc­er; Com­pass gains psy­che­del­ic IP port­fo­lio

4 years ago

Ger­man ra­dio­phar­ma forms an­oth­er Chi­na joint ven­ture; Urovan­t's Gemte­sa pass­es blood pres­sure study

4 years ago

Canada's Bausch to pay $300M in an­titrust set­tle­ment; Cardiff re­leas­es da­ta on mCRC tri­al

4 years ago

Roche to buy up di­ag­nos­tics part­ner TIB Mol­bi­ol; PAQ to part­ner with In­sil­i­co

4 years ago

Look­ing for fresh start fol­low­ing a Duchenne dis­as­ter, Cataba­sis re­brands; Huadong and In­sil­i­co team up in on­col­o­gy

4 years ago

Vac­citech makes short move to new head­quar­ters; En­ter­o­Bi­otix rais­es more than $21M in Se­ries A

4 years ago

Bris­tol My­ers li­cens­es for Evotec mol­e­cule for $20M; FDA ap­proves Im­pel's mi­graine nasal spray Trud­he­sa

4 years ago

In­novent and Gen­Fleet reach deal for KRAS in­hibitor; TCR2 re­ceives FDA's ODD on ga­vo-cel

4 years ago

Lig­and Phar­ma part­ner wins Chi­nese ap­proval for an­ti-PD-1; Brick­ell re­ceives ex­clu­sive rights to DYRK1A in­hibitor

4 years ago

SR One leads $55M round for nasal al­ter­na­tive to EpiPen; Sanofi pulls web­site over ac­cu­ra­cy con­cerns

4 years ago
First page Previous page 26272829303132 Next page Last page
A service from the Financial Times